Click Therapeutics' digital therapeutic (DTx) CT-132 has been approved by the FDA, becoming the first treatment of its type in the US for preventing attacks in people with episodic migraine.

Sio Gene Therapies' litany of clinical disappointments over the last few years has finally led to the demise of the biotech, formerly known as Axovant and one of the 'vant' companies originally ...